Unknown

Dataset Information

0

Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.


ABSTRACT: Macrophages constitute a heterogeneous cell population with pro- (M?1) and anti-inflammatory (M?2) cells. The soluble chitinase-like-protein YKL-40 is expressed in macrophages and various other cell types, and has been linked to a variety of inflammatory diseases, including COPD. Dexamethasone strongly reduces YKL-40 expression in peripheral blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially expressed by M?1 and M?2, b) is decreased by corticosteroids and c) that long-term treatment with inhaled corticosteroids (ICS) affects YKL-40 levels in serum and sputum of COPD patients.Monocytes of healthy subjects were cultured in vitro for 7 days with either GM-CSF or M-CSF (for M?1 and M?2, respectively) and stimulated for 24 h with LPS, TNF?, or oncostatin M (OSM). M?1 and M?2 differentiation was assessed by measuring secretion of IL-12p40 and IL-10, respectively. YKL-40 expression in macrophages was measured by quantitative RT-PCR (qPCR) and ELISA; serum and sputum YKL-40 levels were analyzed by ELISA.Pro-inflammatory M?1 cells secreted significantly more YKL-40 than M?2, which was independent of stimulation with LPS, TNF? or OSM (p < 0.001) and confirmed by qPCR. Dexamethasone dose-dependently and significantly inhibited YKL-40 protein and mRNA levels in M?1. Serum YKL-40 levels of COPD patients were significantly higher than sputum YKL-40 levels but were not significantly changed by ICS treatment.YKL-40 secretion from M?1 cells is higher than from M?2 cells and is unaffected by further stimulation with pro-inflammatory agents. Furthermore, YKL-40 release from cultured monocyte-derived macrophages is inhibited by dexamethasone especially in M?1, but ICS treatment did not change YKL-40 serum and sputum levels in COPD. These results indicate that YKL-40 expression could be used as a marker for M?1 macrophages in vitro, but not for monitoring the effect of ICS in COPD.ClinicalTrials.gov, registration number: NCT00158847.

SUBMITTER: Kunz LI 

PROVIDER: S-EPMC4699377 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3176766 | BioStudies
2019-01-01 | S-EPMC6530174 | BioStudies
2018-08-09 | GSE112260 | GEO
2017-01-01 | S-EPMC5967238 | BioStudies
1000-01-01 | S-EPMC5992772 | BioStudies
2017-01-01 | S-EPMC5593220 | BioStudies
1000-01-01 | S-EPMC3135840 | BioStudies
1000-01-01 | S-EPMC5064386 | BioStudies
2013-01-01 | S-EPMC3864627 | BioStudies
2013-01-01 | S-EPMC3890498 | BioStudies